https://orcid.org/0000-0003-1650-242X
REFERENCES
- CIOMS (Council for International Organizations of Medical Sciences). 2002. International ethical guidelines for biomedical research involving human subjects. https://cioms.ch/publications/product/international-ethical-guidelines-for-biomedical-research-involving-human-subjects-2/
- Cummings, J., G. Lee, P. Nahed, M. E. Z. N. Kambar, K. Zhong, J. Fonseca, and K. Taghva. 2022. Alzheimer’s disease drug development pipeline: 2022. Alzheimer’s & Dementia (New York, N. Y.) 8 (1):e12295. doi:10.1002/trc2.12295.
- Daly, T., and S. Epelbaum. 2022. The accelerated approval of aducanumab invites a rethink of the current model of drug development for Alzheimer’s disease. AJOB Neuroscience :1–4. doi:10.1080/21507740.2022.2048721.
- Djulbegovic, B. 2001. Acknowledgment of uncertainty: A fundamental means to ensure scientific and ethical validity in clinical research. Current Oncology Reports 3 (5):389–95. doi:10.1007/s11912-001-0024-5.
- Espay, A. J., A. Sturchio, L. S. Schneider, and K. Ezzat. 2021. Soluble amyloid-β consumption in Alzheimer’s disease. Journal of Alzheimer’s Disease: JAD 82 (4):1403–15. doi:10.3233/JAD-210415.
- Hardy, J. 2002. Testing times for the “amyloid cascade hypothesis”. Neurobiology of Aging 23 (6):1073–4. doi:10.1016/s0197-4580(02)00042-8.
- Herrup, K. 2015. The case for rejecting the amyloid cascade hypothesis. Nature Neuroscience 18 (6):794–9. doi:10.1038/nn.4017.
- Liu, P. P., Y. Xie, X. Y. Meng, and J. S. Kang. 2019. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal Transduct Target Ther 4:29. doi:10.1038/s41392-019-0063-8.
- Smith, A. D. 2021. Anti-amyloid trials raise scientific and ethical questions. BMJ (Clinical Research ed.) 372:n805. doi:10.1136/bmj.n805.